Mr. Wickholm has extensive senior management and leadership experience from AstraZeneca. He has a strong track record from general management and commercial roles covering various therapeutic areas. Wickholm has also had international assignments and his last position in AstraZeneca was Regional Business Development CEEMEA, (Central-, Eastern- Europe, Middle East, Africa). In business development Wickholm has experience from both sell- and buy-side, from search, through assessments, evaluations, due diligence and negotiations to closure of deals. Wickholm has a BSc in Business Administration and Economics – International Business from Uppsala University and a Postgraduate diploma in Business Management and Finance from Warwick Business School, UK.
|Andrew Saunders, M.D., FFPM
CMO (Chief Medical Officer)
Dr. Saunders has worked in haemato-oncology since 1992, in both clinical practice and the pharmaceutical and biotech industry. He has extensive experience in all aspects and phases of heamato-oncology drug development, and he has held positions of increasing responsibility including Clinical Research Physician at Eli-Lilly & company and Global Clinical Science Leader for Rituximab at Hoffman-La Roche. Prior to joining Lytix Biopharma, Dr. Saunders both founded and acted as Managing Director of Linden Oncology Limited, a consultancy providing strategic and clinical development haemato-oncology expertise to biotech and pharmaceutical companies globally. Dr. Saunders obtained his medical degree from Trinity College Dublin, Rep. of Ireland in 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, U.K.
|Wenche Marie Olsen, PhD
COO (Chief Operating Officer)
Dr. Olsen has broad experience within research, development and management of new drug products in pharmaceutical and biotech industry. Dr. Olsen was the CEO of Lauras, a Norwegian HIV biotech company, since start-up and has held various positions in Nycomed/GE Healthcare. Dr. Olsen has also extensive experience from commercialization and business development from the Life Science sector (Oslo Research Park, 4BIO). In addition, she has held public board positions (the Norwegian Research Council, the Norwegian Bioindustry Association) and serves now as a board member in Medinnova. Dr. Olsen joined Lytix Biopharma in December 2007. She received her PhD in medical biochemistry from the National Hospital, University of Oslo.
|Øystein Rekdal, PhD
Co-founder and CSO (Chief Scientific Officer)
Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996. His postdoctoral work was focusing on oncolytic peptides and their abilities to induce potent tumor specific immune responses. This research forms the basis of Lytix Biopharma’s oncolytic peptide platform. Dr. Rekdal is leading the collaboration with several distinguished researchers and institutions to further explore the unique ability of oncolytic peptides to generate an immunogenic tumor microenvironment. He also serves as a professor at the University of Tromsø in Norway.
Torbjørn Furuseth, M.D.
Dr. Furuseth has broad experience from most aspects within life sciences sector. Before joining Lytix Biopharma he was in the executive management team at Aker BioMarine responsible for Innovation, including science documentation, product development patent prosecution and litigation. He also has experience from sales processes, due diligence, negotiations and transactions in life sciences. Dr. Furuseth has six years of experience as management consultant at McKinsey & Co serving clients within the Pharma and Health Care practice on commercial, operational and strategic topics. Dr. Furuseth obtained his medical degree at Norwegian University of Science and Technology in 2004, and have three years of clinical practice.